PharmaCorp Rx Inc. (TSXV:PCRX)

PharmaCorp Rx Statistics

Total Valuation

PharmaCorp Rx has a market cap or net worth of CAD 55.34 million. The enterprise value is 43.55 million.

Market Cap	55.34M
Enterprise Value	43.55M

Important Dates

The next estimated earnings date is Monday, August 18, 2025.

Earnings Date	Aug 18, 2025
Ex-Dividend Date	n/a

Share Statistics

PharmaCorp Rx has 115.30 million shares outstanding. The number of shares has increased by 468.56% in one year.

Current Share Class	115.30M
Shares Outstanding	115.30M
Shares Change (YoY)	+468.56%
Shares Change (QoQ)	-1.91%
Owned by Insiders (%)	13.58%
Owned by Institutions (%)	n/a
Float	99.64M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.65
PB Ratio	1.80
P/TBV Ratio	3.92
P/FCF Ratio	134.98
P/OCF Ratio	124.70
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-76.62
EV / Sales	4.44
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	106.23

Financial Position

The company has a current ratio of 8.58, with a Debt / Equity ratio of 0.03.

Current Ratio	8.58
Quick Ratio	7.63
Debt / Equity	0.03
Debt / EBITDA	n/a
Debt / FCF	2.23
Interest Coverage	-57.20

Financial Efficiency

Return on equity (ROE) is -3.61% and return on invested capital (ROIC) is -4.19%.

Return on Equity (ROE)	-3.61%
Return on Assets (ROA)	-3.77%
Return on Invested Capital (ROIC)	-4.19%
Return on Capital Employed (ROCE)	-3.37%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.52
Inventory Turnover	n/a

Taxes

In the past 12 months, PharmaCorp Rx has paid 1,279 in taxes.

Income Tax	1,279
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -20.00% in the last 52 weeks. The beta is -5.16, so PharmaCorp Rx's price volatility has been lower than the market average.

Beta (5Y)	-5.16
52-Week Price Change	-20.00%
50-Day Moving Average	0.48
200-Day Moving Average	0.54
Relative Strength Index (RSI)	47.27
Average Volume (20 Days)	23,118

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, PharmaCorp Rx had revenue of CAD 9.80 million and -568,443 in losses. Loss per share was -0.00.

Revenue	9.80M
Gross Profit	3.81M
Operating Income	-1.13M
Pretax Income	-592,888
Net Income	-568,443
EBITDA	n/a
EBIT	-1.13M
Loss Per Share	-0.00

Balance Sheet

The company has 12.94 million in cash and 916,112 in debt, giving a net cash position of 12.02 million or 0.10 per share.

Cash & Cash Equivalents	12.94M
Total Debt	916,112
Net Cash	12.02M
Net Cash Per Share	0.10
Equity (Book Value)	30.82M
Book Value Per Share	0.27
Working Capital	13.22M

Cash Flow

In the last 12 months, operating cash flow was 443,803 and capital expenditures -33,793, giving a free cash flow of 410,010.

Operating Cash Flow	443,803
Capital Expenditures	-33,793
Free Cash Flow	410,010
FCF Per Share	0.00

Margins

Gross margin is 38.85%, with operating and profit margins of -11.57% and -5.80%.

Gross Margin	38.85%
Operating Margin	-11.57%
Pretax Margin	-6.05%
Profit Margin	-5.80%
EBITDA Margin	n/a
EBIT Margin	-11.57%
FCF Margin	4.18%

Dividends & Yields

PharmaCorp Rx does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-468.56%
Shareholder Yield	n/a
Earnings Yield	-1.03%
FCF Yield	0.74%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

PharmaCorp Rx has an Altman Z-Score of 8.71 and a Piotroski F-Score of 2.

Altman Z-Score	8.71
Piotroski F-Score	2